-
1
المؤلفون: Félix Couture, Victoria Atkinson, Steven L. McCune, Alexander M. Menzies, Geoffrey T. Gibney, Andrew G. Hill, Georgina V. Long, Cuizhen Niu, Michael P. Brown, Blanca Homet Moreno, Stéphane Dalle, Steven J. O'Day, Caroline Robert, Matteo S. Carlino, Marcus O. Butler, Nageatte Ibrahim, Adi Diab, Jonathan Cebon
المصدر: Clin Cancer Res
مصطلحات موضوعية: Cancer Research, medicine.medical_specialty, Skin Neoplasms, Ipilimumab, Pembrolizumab, Antibodies, Monoclonal, Humanized, Gastroenterology, Article, law.invention, Randomized controlled trial, law, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Adverse effect, Melanoma, business.industry, medicine.disease, Regimen, Oncology, Cohort, Toxicity, business, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f67743e03a6f91b67256825f8dfc5bcTest
https://doi.org/10.1158/1078-0432.ccr-21-0793Test -
2
المؤلفون: James Larkin, Jeffrey S. Weber, F. Stephen Hodi, Paolo A. Ascierto, Roger Olofsson Bagge, Georgina V. Long, Alexander C.J. van Akkooi, Jacob Schachter, Caroline Robert, Lars Ny
المصدر: Melanoma Research. 31:181-185
مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Ipilimumab, Dermatology, Pembrolizumab, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, Clinical endpoint, Humans, Medicine, Neoplasm Metastasis, Stage (cooking), Melanoma, Randomized Controlled Trials as Topic, business.industry, medicine.disease, Clinical trial, 030104 developmental biology, 030220 oncology & carcinogenesis, Female, Immunotherapy, Nivolumab, business, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3a480cb93e62763c98a1eb0a61f5b12Test
https://doi.org/10.1097/cmr.0000000000000719Test -
3
المؤلفون: Rutger H. T. Koornstra, Sandrine Marreaud, Victoria Atkinson, Andrey Meshcheryakov, Christian U. Blank, Piotr Rutkowski, Jean-Jacques Grob, Leonel Hernandez-Aya, Clemens Krepler, Michal Kicinski, Dirk Schadendorf, Paolo A. Ascierto, Caroline Robert, Mario Mandalà, Susana Puig, Nageatte Ibrahim, Alexander C.J. van Akkooi, Adnan Khattak, Stéphane Dalle, Georgina V. Long, James Larkin, Shahneen Sandhu, Rahima Jamal, Matteo S. Carlino, Alfonsus J M van den Eertwegh, Ralf Gutzmer, Anna Maria Di Giacomo, Andrew Haydon, Alexander M.M. Eggermont, Stefan Suciu, Paul Lorigan
المساهمون: CCA - Cancer Treatment and quality of life, Medical oncology
المصدر: Journal of Clinical Oncology, 38, 3925-3936
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A M, Meshcheryakov, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, van Akkooi, A C J, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2020, ' Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial ', Journal of Clinical Oncology, vol. 38, no. 33, pp. 3925-3936 . https://doi.org/10.1200/JCO.20.02110Test
Journal of Clinical Oncology, 38(33), 3925-3936. American Society of Clinical Oncology
Journal of Clinical Oncology
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A M, Meshcheryakov, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Di Giacomo, A M, van den Eertwegh, A J M, Grob, J J, Gutzmer, R, Jamal, R, Lorigan, P C, van Akkooi, A C J, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2020, ' Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma : Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 38, no. 33, pp. 3925-3936 . https://doi.org/10.1200/JCO.20.02110Test
Journal of Clinical Oncology, 38, 33, pp. 3925-3936مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Medizin, Pembrolizumab, Placebo, law.invention, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, Original Reports, medicine, Stage III melanoma, Melanoma, Chemotherapy, Manchester Cancer Research Centre, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, Cancer, medicine.disease, Clinical trial, 030104 developmental biology, 030220 oncology & carcinogenesis, business, Adjuvant
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19c8d8800862ec580f808001677c9a85Test
https://hdl.handle.net/2066/228545Test -
4
المؤلفون: Christian U. Blank, Stéphane Dalle, Alexander M.M. Eggermont, Sandrine Marreaud, Matteo S. Carlino, Alfonsus J. M. van den Eertwegh, Stefan Suciu, Nageatte Ibrahim, Rahima Jamal, Paolo A. Ascierto, Alexander C.J. van Akkooi, Michal Kicinski, Piotr Rutkowski, Georgina V. Long, Dirk Schadendorf, Ralf Gutzmer, Shahneen Sandhu, Andrew Haydon, Victoria Atkinson, Susana Puig, Adnan Khattak, Anna Maria Di Giacomo, Clemens Krepler, Mario Mandalà, Rutger H. T. Koornstra, Caroline Robert, Jean-Jacques Grob, Leonel Hernandez-Aya, Paul Lorigan, James Larkin
المساهمون: Medical oncology, CCA - Cancer Treatment and quality of life, AII - Cancer immunology
المصدر: Jama Oncology, 6, 519-527
Eggermont, A M M, Kicinski, M, Blank, C U, Mandala, M, Long, G V, Atkinson, V, Dalle, S, Haydon, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Krepler, C, Ibrahim, N, Marreaud, S, van Akkooi, A, Robert, C & Suciu, S 2020, ' Association between Immune-Related Adverse Events and Recurrence-Free Survival among Patients with Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial ', JAMA Oncology, vol. 6, no. 4, pp. 519-527 . https://doi.org/10.1001/jamaoncol.2019.5570Test
Eggermont, A M M, Kicinski, M, Blank, C U, Mandala, M, Long, G V, Atkinson, V, Dalle, S, Haydon, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Krepler, C, Ibrahim, N, Marreaud, S, van Akkooi, A, Robert, C & Suciu, S 2020, ' Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo : A Secondary Analysis of a Randomized Clinical Trial ', JAMA oncology . https://doi.org/10.1001/jamaoncol.2019.5570Test
Jama Oncology, 6, 4, pp. 519-527
JAMA Oncology, 6(4), 519-527. American Medical Associationمصطلحات موضوعية: Adult, Male, Cancer Research, medicine.medical_specialty, Population, Medizin, Pembrolizumab, Placebo, Antibodies, Monoclonal, Humanized, Disease-Free Survival, law.invention, Placebos, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, 0302 clinical medicine, Randomized controlled trial, Double-Blind Method, law, Internal medicine, Medicine, Humans, 030212 general & internal medicine, education, Adverse effect, Melanoma, Aged, Neoplasm Staging, Proportional Hazards Models, education.field_of_study, Manchester Cancer Research Centre, business.industry, Proportional hazards model, ResearchInstitutes_Networks_Beacons/mcrc, Hazard ratio, Middle Aged, Ipilimumab, Clinical trial, Oncology, 030220 oncology & carcinogenesis, Female, Neoplasm Recurrence, Local, business
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9b431bc34ae329792ac7bd923376806Test
https://hdl.handle.net/2066/218502Test -
5
المؤلفون: Christoph Hoeller, Marie-Francoise Avril, Pietro Quaglino, François Aubin, Lars Bastholt, Takashi Inozume, Virginia Ferraresi, Michael B. Jameson, Kevin B. Kim, Oliver Bechter, Dirk Schadendorf, Kenji Yokota, Carmen Loquai, Maria-Jose Passos, Inge Marie Svane, Michele Maio, Catherine Barrow, Frank Meiss, Nageatte Ibrahim, Andrzej Mackiewicz, Phillip Parente, Tatsuya Takenouchi, Caroline Dutriaux, Piotr Rutkowski, Alfonsus J M van den Eertwegh, Paola Queirolo, Catriona M. McNeil, Peter Mohr, Felix Kiecker, Susana Puig, Friedegund Meier, Lutz Kretschmer, Alexander C.J. van Akkooi, Alex Menzies, Timothy Crook, Christian U. Blank, Suzana Matkovic, Michael C. Brown, Ragini R. Kudchadkar, Max Levin, Rüdiger Hein, Tanja Skytta, Gerald P. Linette, Clemens Krepler, Adnan Khattak, Ernest Marshall, Joseph Kerger, Oddbjorn Straume, Laurent Mortier, Jochen Utikal, Micaela Hernberg, James Larkin, Yoshio Kiyohara, Mario Mandalà, Henrik Schmidt, Daniil Stroyakovskiy, Pablo Luis Ortiz Romero, Naoya Yamazaki, John Walker, Anna Maria Di Giacomo, Lionel Geoffrois, Jean-Philippe Lacour, Caroline Robert, Vincent Descamps, Shahneen Sandhu, Gil Bar-Sela, Paul C. Nathan, Marcin Dzienis, Ralf Gutzmer, Claus Garbe, Andrey Meshcheryakov, Patrick Combemale, Martin Fehr, Guzel Mukhametshina, Helena Kapiteijn, Geke A. P. Hospers, Jun Aoi, Andrew Haydon, Rutger H. T. Koornstra, Marie-Thérèse Leccia, Sigrun Hallmeyer, Pier Francesco Ferrucci, Jean-Jacques Grob, Leonel Hernandez-Aya, Jan-Christoph Simon, Vanna Chiarion Sileni, Alain Algazi, Lidija Sekulovic, Sandrine Marreaud, Bernard Fitzharris, Jacob Schachter, Xinni Song, Wolf-Henning Boehncke, Rahima Jamal, Paul Lorigan, Maureen J.B. Aarts, Reinhard Dummer, Mike McCrystal, César Martins, Reiner Hofmann-Wellenhof, Alexander M.M. Eggermont, Carola Berking, Elaine Dunwoodie, Bernard Guillot, Michal Kicinski, Philippe Saiag, Céleste Lebbé, Thierry Lesimple, Stefan Suciu, Michal Lotem, Paula Ferreira, Mohammed M. Milhem, Laurent Machet, Patrick Terheyden, Anna Katharina Winge-Main, Peter Hersey, Jean-Francois Baurain, Axel Hauschild, Stéphane Dalle, Jean-Philippe Arnault, Paolo A. Ascierto, Gerard Groenewegen, Florent Grange, Georgina V. Long, Victoria Atkinson, Philippa Corrie, Matteo S. Carlino, Thomas Jouary, Daniel Hendler, Richard Casasola, Ashita Waterston, Jessica C. Hassel
المساهمون: University Medical Center [Utrecht], Azienda Ospedaliera Ospedale Papa Giovanni XXIII [Bergamo, Italy], The University of Sydney, Princess Alexandra Hospital, Brisbane, University of Queensland [Brisbane], Centre Léon Bérard [Lyon], Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), N.N. Blokhin National Medical Research Center of Oncology, Edith Cowan University (ECU), Royal Marsden NHS Foundation Trust, Universitat de Barcelona (UB), Instituto de Salud Carlos III [Madrid] (ISC), Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology (MCMCC), Universitätsklinikum Essen [Universität Duisburg-Essen] (Uniklinik Essen), Radboud University Medical Center [Nijmegen], Washington University School of Medicine in St. Louis, Washington University in Saint Louis (WUSTL), University Hospital of Siena, Amsterdam UMC - Amsterdam University Medical Center, Hôpital de la Timone [CHU - APHM] (TIMONE), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hannover Medical School [Hannover] (MHH), Centre Hospitalier de l'Université de Montréal (CHUM), Université de Montréal (UdeM), The Christie NHS Foundation Trust [Manchester, Royaume-Uni], Merck & Co. Inc, European Organisation for Research and Treatment of Cancer [Bruxelles] (EORTC), European Cancer Organisation [Bruxelles] (ECCO), Institut Gustave Roussy (IGR), Oncologie dermatologique, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Montpellier (UM), Internal medicine, CCA - Cancer Treatment and quality of life
المصدر: EORTC Melanoma Group 2021, ' Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial ', The Lancet Oncology, vol. 22, no. 5, pp. 643-654 . https://doi.org/10.1016/S1470-2045Test(21)00065-6
Lancet Oncology, 22, 643-654
Lancet Oncology, 22, 5, pp. 643-654
Lancet Oncology
Lancet Oncology, 2021, 22 (5), pp.643-654. ⟨10.1016/S1470-2045(21)00065-6⟩
The Lancet Oncology, 22(5), 643-654. Lancet Publishing Groupمصطلحات موضوعية: Male, Skin Neoplasms, Medizin, Pembrolizumab, law.invention, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], MESH: Aged, 80 and over, 0302 clinical medicine, Randomized controlled trial, law, Monoclonal, 80 and over, MESH: Double-Blind Method, 030212 general & internal medicine, Neoplasm Metastasis, Humanized, Melanoma, MESH: Aged, Aged, 80 and over, education.field_of_study, MESH: Middle Aged, Hazard ratio, MESH: Neoplasm Staging, Middle Aged, Oncology, 030220 oncology & carcinogenesis, Female, Adult, Aged, Antibodies, Monoclonal, Humanized, Double-Blind Method, Humans, Neoplasm Staging, medicine.medical_specialty, MESH: Melanoma, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, Placebo, Antibodies, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Internal medicine, medicine, Adjuvant therapy, education, Cancer staging, MESH: Humans, business.industry, MESH: Skin Neoplasms, MESH: Adult, MESH: Neoplasm Metastasis, MESH: Male, Clinical trial, MESH: Antibodies, Monoclonal, Humanized, business, MESH: Female
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca46af8de45fdf5ffd9d70f717e94208Test
https://research.vumc.nl/en/publications/8aae177c-dfa8-4325-b8c2-e7b1d7339027Test -
6
المؤلفون: Anna Maria Di Giacomo, Georgina V. Long, Vanna Chiarion-Sileni, Helen Gogas, Micaela Hernberg, Kerry J. Savage, Laurent Mortier, Francesco Cognetti, Benjamin Brady, Cornelia Mauch, Caroline Robert, Julie Charles, Ana Arance, Piotr Rutkowski, Catriona M. McNeil, Lars Ny, Jesus Zoco, Ewa Kalinka, Sandra Re, Dirk Schadendorf, Victoria Atkinson, Caroline Dutriaux, Catalin Mihalcioiu, Paolo A. Ascierto, Jessica C. Hassel, Henrik Schmidt, Céleste Lebbé
المساهمون: HUS Comprehensive Cancer Center, Clinicum, Department of Oncology, Helsinki University Hospital Area
المصدر: Journal of Clinical Oncology
Robert, C, Long, G V, Brady, B, Dutriaux, C, Di Giacomo, A M, Mortier, L, Rutkowski, P, Hassel, J C, McNeil, C M, Kalinka, E A, Lebbé, C, Charles, J, Hernberg, M M, Savage, K J, Chiarion-Sileni, V, Mihalcioiu, C, Mauch, C, Arance, A, Cognetti, F, Ny, L, Schmidt, H, Schadendorf, D, Gogas, H, Zoco, J, Re, S, Ascierto, P A & Atkinson, V 2020, ' Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 38, no. 33, pp. 3937-3946 . https://doi.org/10.1200/JCO.20.00995Testمصطلحات موضوعية: 0301 basic medicine, Oncology, Proto-Oncogene Proteins B-raf, Cancer Research, medicine.medical_specialty, 3122 Cancers, Medizin, Ipilimumab, Pembrolizumab, law.invention, 03 medical and health sciences, 0302 clinical medicine, Antineoplastic Agents, Immunological, Randomized controlled trial, law, Internal medicine, Original Reports, medicine, Humans, METASTATIC MELANOMA, Progression-free survival, PEMBROLIZUMAB, Survival rate, Melanoma, Antineoplastic Agents, Alkylating, COMPLETE RESPONSE, business.industry, IPILIMUMAB, Wild type, Progression-Free Survival, 3. Good health, Clinical trial, Dacarbazine, Survival Rate, 030104 developmental biology, Nivolumab, 030220 oncology & carcinogenesis, SURVIVAL, Metastatic melanoma, Complete response, Pembrolizumab, Ipilimumab, Survival, business, medicine.drug
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56e136a7f3cebfa513b285e44ed047f9Test
http://hdl.handle.net/10138/324446Test -
7
المؤلفون: Jin Zhang, Jeffrey S. Weber, James R. Anderson, Anthony M. Joshua, Adil Daud, Scot Ebbinghaus, Richard F. Kefford, Richard W. Joseph, Amita Patnaik, Peter Hersey, Wen-Jen Hwu, Omid Hamid, Caroline Robert, Tara C. Gangadhar, Antoni Ribas, Scott J. Diede, F. Stephen Hodi, Hassane M. Zarour, Roxana S. Dronca, Jedd D. Wolchok
المصدر: Journal of Clinical Oncology. 36:1668-1674
مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Skin Neoplasms, Pembrolizumab, Antibodies, Monoclonal, Humanized, Disease-Free Survival, law.invention, Cohort Studies, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Randomized controlled trial, law, Carcinoma, Non-Small-Cell Lung, Internal medicine, medicine, Carcinoma, Humans, Neoplasm Metastasis, Melanoma, Aged, business.industry, Middle Aged, medicine.disease, Discontinuation, Clinical trial, 030104 developmental biology, Response Evaluation Criteria in Solid Tumors, 030220 oncology & carcinogenesis, Monoclonal, Female, business, Cohort study
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cc80c548aef4a43c6afca48a89a7e9fTest
https://doi.org/10.1200/jco.2017.75.6270Test -
8
المؤلفون: Jean-Jacques Grob, Michal Lotem, Christian U. Blank, Catriona M. McNeil, Jacob Schachter, James Larkin, Adil Daud, Omid Hamid, Laurent Mortier, Ana Arance, Matteo S. Carlino, Bart Neyns, Paul Lorigan, Shu Chih Su, Antoni Ribas, Teresa M. Petrella, Georgina V. Long, Clemens Krepler, Caroline Robert, Nageatte Ibrahim
المساهمون: Clinical sciences, Medical Oncology, Laboratory for Medical and Molecular Oncology, Laboratory of Molecullar and Cellular Therapy
مصطلحات موضوعية: Adult, Male, 0301 basic medicine, advanced melanoma, medicine.medical_specialty, Phases of clinical research, Ipilimumab, Pembrolizumab, Antibodies, Monoclonal, Humanized, Drug Administration Schedule, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Humans, Medicine, Progression-free survival, ipilimumab, KEYNOTE-006, Melanoma, Aged, Neoplasm Staging, Proportional Hazards Models, Medicine(all), business.industry, Proportional hazards model, Hazard ratio, Middle Aged, Progression-Free Survival, Clinical trial, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Female, pembrolizumab, business, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b24205b257822ddbf30cee39b4dc1f9Test
https://biblio.vub.ac.be/vubirTest/(e2696151-46a7-4118-9960-b3e5b06df058).html -
9
المؤلفون: Ana Arance, Thomas F. Gajewski, Christian Caglevic, Mark M. Jones, Janet Maleski, Caroline Robert, Lev V. Demidov, Omid Hamid, Tae Min Kim, Scott J. Diede, Stéphane Dalle, Tara C. Mitchell, Matteo S. Carlino, Reinhard Dummer, Georgina V. Long, James R. Anderson, Jean-Jacques Grob, James Larkin
المساهمون: University of Zurich, Long, Georgina V
المصدر: Ann Transl Med
مصطلحات موضوعية: 0301 basic medicine, Adult, Male, medicine.medical_specialty, Population, 610 Medicine & health, Pembrolizumab, Placebo, Antibodies, Monoclonal, Humanized, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, Double-Blind Method, law, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Oximes, medicine, Humans, Progression-free survival, education, Melanoma, Aged, education.field_of_study, Sulfonamides, business.industry, Hazard ratio, 10177 Dermatology Clinic, Middle Aged, Interim analysis, Progression-Free Survival, Clinical trial, Editorial Commentary, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Female, 2730 Oncology, business
وصف الملف: 805_Long_GV._et_al._Epacadostat_plus_pembrolizumab_versus_placebo_plus_pembrolizumab_in_patients_with_unresectable_or_metastatic_melanoma_etc._Lancet_Oncol_2019.pdf - application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::994d50fe36f67262fd59a66df91baccbTest
https://www.zora.uzh.ch/id/eprint/172887Test/ -
10
المؤلفون: Richard W. Joseph, Christine Mateus, Amita Patnaik, Roxana S. Dronca, Omid Hamid, Adil Daud, F. Stephen Hodi, Scot Ebbinghaus, Wen-Jen Hwu, Jeroen Elassaiss-Schaap, Peter D. Boasberg, Richard F. Kefford, Antoni Ribas, Tara C. Gangadhar, S. Peter Kang, Bartosz Chmielowski, Anthony M. Joshua, Jedd D. Wolchok, Caroline Robert, Kevin Gergich, Hassane M. Zarour, Xiaoyun Nicole Li, Robert Iannone, Michael A. Postow, Jeffrey S. Weber
المصدر: The Lancet. 384:1109-1117
مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Skin Neoplasms, Adolescent, Programmed Cell Death 1 Receptor, Antineoplastic Agents, Ipilimumab, Pembrolizumab, Antibodies, Monoclonal, Humanized, Gastroenterology, law.invention, Young Adult, Randomized controlled trial, law, Internal medicine, medicine, Clinical endpoint, Humans, Adverse effect, Melanoma, Fatigue, Aged, Dose-Response Relationship, Drug, business.industry, Pruritus, Antibodies, Monoclonal, General Medicine, Middle Aged, Rash, Surgery, Clinical trial, Treatment Outcome, Drug Resistance, Neoplasm, Response Evaluation Criteria in Solid Tumors, Female, Drug Eruptions, medicine.symptom, business, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::567ff1bc306785d4655b459c1c335c52Test
https://doi.org/10.1016/s0140-6736Test(14)60958-2